Our Science

Publications and Presentations

search
Date
Title
April 2022
Oral Ibrexafungerp Outcomes in Patients with Invasive Candidiasis and Candidemia from the FURI and CARES Studies ECCMID
April 2022
Outcomes of Oral Ibrexafungerp in the Treatment of 18 Patients with Candida auris Infections, from the CARES Study ECCMID
October 2021
Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)
October 2021
Outcomes of Oral Ibrexafungerp in Refractory Patients from an Interim Analysis of a Phase 3 Open-Label Study (FURI) TIMM
October 2021
Outcomes of Oral Ibrexafungerp by Pathogen from Two Open-label Studies of Patients with Serious Fungal Infections (FURI and CARES) TIMM
September 2021
Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI) IDWeek
September 2021
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis (DOVE)
September 2021
Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal Candidiasis and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI) IDWeek
March 2021
A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vivo Activity in a Murine Model of Hematogenously Disseminated Candida albicans Antimicrobial Agents and Chemotherapy Sherman Chu,a,b Lisa Long,a,dThomas S. McCormick,a Katyna Borroto-Esoda,c Stephen Baratc Mahmoud A. Ghannouma,d
March 2021
A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates Antimicrobial Agents and Chemotherapy Sherman Chu,a,b Lisa Long,a,d Rania Sherif,a,d Thomas S. McCormick,a Katyna Borroto-Esoda,c Stephen Barat,cMahmoud A. Ghannouma,d
< PrevNext >